Drugs / lupatadine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06709092 | Mar → Dec 2024 overdue | allergic rhinitis | Cheng Lei | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lupatadine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06709092 ↗ |
| Known as | Luso | “For patients with AR, patients were given lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals) 1 tablet once daily at bedtime for 14 days.” NCT06709092 ↗ |
| Action | Inhibit | “Lupatadine fumarate has the dual effects of antihistamine and platelet-activating factor (PAF), and it is the only potent and highly effective allergy drug with both...” NCT06709092 ↗ |